Johnson & Johnson Acquires Intra-Cellular Pharmaceuticals

Johnson & Johnson had recently announced their takeover plan for Intra-Cellular Pharmaceuticals, which provides them with the resources and tools to expand their presence in the pharmaceutical sector. The increase in their stock price suggests a good start, as the deal places them at around $14.6 billion, with J&J paying $132 per share, a 39% increase over Intra-Cellular’s share price as of last Friday. The larger portion of the deal is focused on the neurology market, an area in which they have shown strong interest.